TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05958121: A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors

Sponsor: Immatics Biotechnologies GmbH · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$1,570,800

Rescue Site Savings

+$1,021,020

Unlock Full NCT05958121 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05958121 Rescue Dossier →